Lucerastat (Standard)
Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS) . Lucerastat has the potential for Fabry disease study[1][2].
Product Specifications
CAS Number
141206-42-0
Product Name Alternative
NB-DGJ (Standard) ; N- (n-Butyl) deoxygalactonojirimycin (Standard)
UNSPSC
12352005
Target
Glucosylceramide Synthase (GCS) ; Reference Standards
Related Pathways
Neuronal Signaling; Others
Field of Research
Metabolic Disease
Smiles
O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O
Molecular Formula
C10H21NO4
Molecular Weight
219.28
References & Citations
[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
